Vinblastine

HOPA Survey Reveals Frequent Drug Shortages and Increased Risks for Medication Errors

Retrieved on: 
Friday, June 3, 2022
Vinblastine, Time, CARES Act, Mayo Clinic Cancer Center, Hotel manager, Effect, Legislation, Pharmacist, BCG, HOPA, Doctor of Pharmacy, Organization, Vincristine, Government, Student, COVID-19, National, Research, JCO, Organic acid, Pharmacy, Public health, Patient safety, Cancer, Medical imaging, Medicine

MILWAUKEE, June 3, 2022 /PRNewswire-PRWeb/ -- A survey of US oncology pharmacists recently published in JCO® Oncology Practice reports that oncology drug shortages continue to present serious barriers to providing effective cancer care. Disruptions caused by drug shortages can lead to delays in the timing of chemotherapy treatments, alterations in the dose or regimen administered, or even missed doses when alternative agents are unavailable. Read the JCO article.

Key Points: 
  • MILWAUKEE, June 3, 2022 /PRNewswire-PRWeb/ -- A survey of US oncology pharmacists recently published in JCO Oncology Practice reports that oncology drug shortages continue to present serious barriers to providing effective cancer care.
  • The National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association (HOPA) Survey investigated the impact of oncology drug shortages in a variety of practice settings in the United States.
  • Sixty-three percent of institutions reported one or more drug shortages per month, with a 34% increase in 2019 from 2018.
  • A recent HOPA Drug Shortages Issue Brief provides recommendations for collaborative efforts among drug manufacturers, healthcare professionals, patient advocacy organizations, and government agencies to help mitigate disruptions caused by oncology drug shortages.

Intensity Therapeutics Announces New Clinical Data Presentation for its Lead Asset, INT230-6, in Breast Cancer, at the 2021 San Antonio Breast Cancer Symposium® in December

Retrieved on: 
Tuesday, November 30, 2021
Patient, Fox Chase Cancer Center, Bristol Myers Squibb, Ontario Institute for Cancer Research, Diffusion, Hoag (health network), Cancer, Ipilimumab, Merck, Company, Neoplasm, Woman, Vinblastine, Breast, Merck Sharp & Dohme Federal Credit Union, Breast cancer, Malignancy, Ottawa Hospital Research Institute, National Cancer Institute, Cooperative research and development agreement, Poster, Cisplatin, Pembrolizumab, Safety, Intensity, University Medical Center, Publication, Development, Campus, NCI, Immune system, CRADA, Therapy, Immunosuppression, NCI-designated Cancer Center, Colon, Pharmaceutical industry

INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection.

Key Points: 
  • INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection.
  • Intensity Therapeutics, Inc. is a privately held, clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers.
  • This press release contains forward-looking statements regarding Intensity Therapeutics' plans, future operations and objectives.
  • These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.

Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO

Retrieved on: 
Friday, November 12, 2021
Cancer, Therapy, Breast, Poster, Safety, Ottawa Hospital Research Institute, Bristol Myers Squibb, Intensity, Pain, Columbia University Vagelos College of Physicians and Surgeons, STS, Review, Colon, CTOS, Merck Sharp & Dohme Federal Credit Union, NCI, Injection, Cisplatin, Woman, Ontario Institute for Cancer Research, National Cancer Institute, Survival, Patient, Immunosuppression, Diffusion, FDA, Ipilimumab, Sarcoma, Neoplasm, Division, Pembrolizumab, Publication, Fatigue, Hematology, Vinblastine, NCT, LDH, Surgeon, ECOG, Agency, MD, SHAO, Merck, Immune system, Appetite, Cooperative research and development agreement, BMS, Haematoxylin, Eosin, Company, Development, CRADA, Physician, Assistant, Pharmaceutical industry, Vaccine

These results provide further evidence to continue studying this novel therapeutic drug approach."

Key Points: 
  • These results provide further evidence to continue studying this novel therapeutic drug approach."
  • The data presented included results from 19 patients with different metastatic sarcomas treated with INT230-6 either as a monotherapy (n=10), or in combination with a checkpoint inhibitor (n=8) primarily ipilimumab.
  • For sarcoma subjects dosed to >40% of their total tumor burden, approximately 60% of subjects will be alive at 1 year.
  • Intensity Therapeutics, Inc. is a privately held, clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers.